Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.

Leukemia & lymphoma - 1 Feb 2015

Melchardt Thomas, Weiss Lukas, Hufnagl Clemens, Neureiter Daniel, Kemmerling Ralf, Morre Patrick, Boekstegers Ann, Hopfinger Georg, Auberger Jutta, Steinkirchner Susanne, Pleyer Lisa, Greil Richard, Egle Alexander

Abstract excerpt

Clinical and/or biological risk factors are needed to identify elderly patients with aggressive B-cell lymphoma able to receive full-dose R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) treatment. We present a retrospective analysis of 83 patients≥75 years of age (range: 75-97) who were diagnosed with aggressive B cell lymphoma between 2004 and 2011 in our clinic. R-CHOP-like therapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Oxidoreductases
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Leukopenia

Share to Lymphoma, B-Cell

Share to Prednisone

Share to Rituximab

Share to Vincristine

Source

Identifiers

PMID: 24798743
DOI: 10.3109/10428194.2014.916798

Genes

CBR3
MLH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.PMID 24798743Read ↗

TP53 mutation and survival in aggressive B cell lymphoma.Semantic proximity Read ↗

Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas.Semantic proximity Read ↗

Pharmacogenetic considerations for non-Hodgkin's lymphoma therapy.Semantic proximity Read ↗

Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.Semantic proximity Read ↗

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Semantic proximity Read ↗

Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.Semantic proximity Read ↗

Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.Semantic proximity Read ↗

Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients.Semantic proximity Read ↗

Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.Semantic proximity Read ↗

Risk factors for anthracycline-associated cardiotoxicity.Semantic proximity Read ↗

Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified.Semantic proximity Read ↗

Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.